相关实验视频

Updated: Jan 6, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

托莱布鲁丁尼布:首次获得批准

Hannah A Blair¹

¹Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

|November 24, 2025

概括

托莱布鲁丁尼布,一种新的口服布鲁顿药物.

科学领域:

神经科学是一个神经科学.
药理学药理学是指药理学的学科.
免疫学免疫学免疫学

背景情况:

多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
目前的MS治疗旨在减少炎症和控制症状,但在治疗疾病的渐进形式方面仍然存在挑战.
布鲁顿的氨酸激酶 (BTK) 是B细胞发育和免疫细胞功能中的关键信号分子,使其成为MS治疗的目标.

研究的目的:

总结一下托莱布鲁丁尼布的关键发展里程碑.
要突出导致多发性硬化症首次批准托莱布鲁丁尼的监管过程.
为提供托莱布鲁丁尼作为BTK抑制剂的作用机制的概述.

主要方法:

对托莱布鲁丁尼布的临床前和临床试验数据的审查.
对监管机构提交和批准的分析.
托莱布鲁丁尼的药理动力学和药理动力学特性概述.

主要成果:

托莱布鲁丁尼布是一种口服可用的,穿透大脑的BTK抑制剂,在临床研究中已经证明了它的有效性.
该药物于2025年8月26日在阿联首次获得批准,用于治疗非复发的次级渐进性MS.
美国和欧盟正在进行监管审查,这表明全球存在重大兴趣.

结论:

托莱布鲁丁尼布代表了MS治疗的重大进步,提供了一个新的口服治疗选择.
在阿联获得批准标志着一个关键的里程碑,可能为更广泛地获得这种创新疗法铺平道路.
预计将获得进一步的监管批准,扩大进展性多发性硬化症患者的治疗选择.

更多相关视频

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

相关概念视频

FDA Approved Drugs: Changes to Approved Drugs

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...